Inlet Private Wealth LLC Sells 200 Shares of DaVita Inc. (NYSE:DVA)

Inlet Private Wealth LLC reduced its holdings in DaVita Inc. (NYSE:DVA) by 0.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,740 shares of the company’s stock after selling 200 shares during the quarter. DaVita makes up approximately 1.8% of Inlet Private Wealth LLC’s holdings, making the stock its 16th largest holding. Inlet Private Wealth LLC owned about 0.05% of DaVita worth $7,006,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of DaVita by 2.4% during the fourth quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock worth $662,161,000 after purchasing an additional 145,711 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new stake in DaVita during the 4th quarter worth about $30,000. CWM LLC increased its position in DaVita by 35.5% in the 1st quarter. CWM LLC now owns 2,083 shares of the company’s stock valued at $288,000 after acquiring an additional 546 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in shares of DaVita by 644.1% in the first quarter. Los Angeles Capital Management LLC now owns 34,993 shares of the company’s stock worth $4,831,000 after acquiring an additional 30,290 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of DaVita by 18.8% during the first quarter. GAMMA Investing LLC now owns 657 shares of the company’s stock worth $91,000 after purchasing an additional 104 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

Insider Activity at DaVita

In related news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares in the company, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Michael David Staffieri sold 9,539 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares in the company, valued at approximately $36,299,008.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 173,482 shares of company stock worth $27,387,069. Insiders own 2.00% of the company’s stock.

DaVita Stock Down 1.8 %

DVA traded down $2.95 during trading hours on Thursday, hitting $161.87. 219,215 shares of the company’s stock were exchanged, compared to its average volume of 807,013. DaVita Inc. has a 1-year low of $75.14 and a 1-year high of $168.50. The stock’s 50-day moving average is $155.89 and its two-hundred day moving average is $144.28. The stock has a market cap of $13.58 billion, a price-to-earnings ratio of 17.30, a PEG ratio of 0.93 and a beta of 0.87. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The company had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The business’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.08 EPS. Sell-side analysts predict that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DVA. Truist Financial boosted their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. UBS Group upped their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. TD Cowen lifted their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Finally, Bank of America upped their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $159.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.